# Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

Source: https://onco.cc/trials/nct04299191/  
OnCo record `nct04299191` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LAM561 in glioma & glioblastoma, run by Laminar Pharmaceuticals, now recruiting.

## Summary

Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04299191 by Laminar Pharmaceuticals, with 28 participants planned, started 2020-09-01 and due to reach its primary completion in 2026-10. Interventions recorded: LAM561.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04299191
- Phase: 1/2
- Setting: Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
- Sponsor: Laminar Pharmaceuticals
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT04299191: https://clinicaltrials.gov/study/NCT04299191

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [LAM561](https://onco.cc/drugs/lam561/)
- companies: [Laminar Pharmaceuticals](https://onco.cc/companies/laminar-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct04299191.json